MC5523

MC5523 is a specific preparation or chemical extract derived from *Momordica charantia* (bitter melon), investigated primarily as a neuroprotective agent in preclinical studies for Alzheimer's disease[1][3]. In animal models, MC5523 has been shown to attenuate neuronal loss and gliosis, improve memory deficits, reduce amyloid beta oligomer levels and tau protein phosphorylation, and enhance expression of synaptic plasticity markers such as PSD95 and MAP2[1]. When combined with lithium chloride, MC5523 demonstrates synergistic neuroprotective effects, including reduced hepatotoxicity, improved survival, and enhanced cognitive function compared to either agent alone[1][3]. The exact chemical composition and mechanism of action beyond general plant constituents are not fully characterized in the available literature.